Ivabradine vs Digoxin for Heart Failure and Kidney Disease: A Real-World Cohort Study

3,140 propensity-score-matched patients from the TriNetX network show ivabradine was associated with a lower risk of major adverse cardiovascular events compared to digoxin (HR 0.79). This dataset supports a retrospective cohort study comparing two heart rate control drugs in patients with both heart failure and chronic kidney disease. It includes demographic, clinical, laboratory, and medication variables used for matching and outcome analysis.

Use Cases

• Comparative effectiveness research based on propensity-score-matched real-world patient cohorts.
• Risk analysis for major adverse cardiovascular events (MACE) based on medication exposure.
• Secondary analysis of heart failure exacerbation and all-cause mortality outcomes.
• Validation of clinical trial findings in a real-world, multicenter patient population.

Strengths

• Includes 3,140 patients from a large, real-world global research network (TriNetX).
• Uses rigorous propensity-score matching on demographic, clinical, laboratory, and medication variables.
• Provides specific hazard ratios and confidence intervals for primary and secondary outcomes.

Limitations

• Column names and specific variable definitions are not provided in the metadata.
• The exact row count is inconsistently reported (one source lists 'Rows: unknown', another 'Rows: None').
• As supplementary material, the dataset's structure and completeness depend on the primary article.

Provenance

Source

TriNetX global research network

Collection Method

Retrospective cohort study using propensity-score matching.

Time Range

2015 to 2025

Freshness

2026-03-21

Geography

Multicenter, global (from TriNetX network)